Replies to post #203691 on Biotech Values

[north40000]

Potential competition for MEDV/PFE & PC in future from many, including SPHS:

https://www.reddit.com/r/DoTheDD/comments/4vdms4/sphs/

[DewDiligence]

PFE acquires MDVN for $81.50/sh in cash—a 118% premium relative to the closing price on 3/30/16 (when the price started rising in anticipation of a buyout):

http://finance.yahoo.com/news/pfizer-acquire-medivation-104600375.html

The nominal deal value is $14.0B. There is no CVR for Talazoparib, but MDVN’s webcast on 7/6/16 may have helped boost the buyout price (#msg-123722679).